Syngene International – improving access to medicines
What does the company do?
India’s leading contract research organisation (CRO), Syngene International supports R&D programmes of global innovative companies, mainly in the fields of pharmaceutical and biotech and also in other industrial sectors such as agrochemical, nutrition, animal health, specialty and performance chemicals. The company has more recently added contract manufacturing organisation (CMO) capabilities to offer clients an end-to-end continuum of services. Syngene is a 70% subsidiary of the reputable Biocon group in India.
Why do we like the investment?
The company has a role to play in improving public healthcare system by driving innovation, operational efficiency and productivity. With longer R&D development cycles and rising costs, global pharmaceutical companies have started to partner with CROs to a) increase efficiencies, b) increase speed to market and c) reduce costs. Syngene’s value proposition to clients is to offer world-class capabilities at more affordable prices. Notable collaborations include Baxter, Bristol-Myers Squibb, Amgen and Herbalife.
Syngene upholds itself to high corporate governance standards, best-in-class product quality management as certified by ISO and OHSAS and improving on their carbon footprint having now switched to the use of solar power, a source of energy that is abundant and cheap in India.
Companies selected for illustrative purposes only to demonstrate the investment management style described herein and not as an investment recommendation or indication of future performance.
In which year did we first invest?
Where is their head office?